Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 511 | Diphenhydramine Hydrochloride 14mg/5ml Expectorant | R06AA52-110-L21-01-XXX | C | Cough | None | ADULT : 5 - 10 ml 2 - 3 times daily. |
| 512 | Diphenhydramine Hydrochloride 7 mg/5 ml Expectorant | R06AA52-110-L90-03-XXX | C | Cough | None | CHILD 6-12 years: 2.5 to 5 ml 2-3 times daily CHILD 2-5 years: 2.5 ml 2-3 times daily NOT to be used in children less than 2 years in age |
| 513 | Diphenoxylate HCl 2.5mg with Atropine Sulphate 0.025mg Tablet | A07DA01-922-T10-01-XXX | B | Symptomatic treatment of acute and chronic diarrhoea | None | ADULT: 2 tablets 4 times daily, later reduced when diarrhoea is controlled. Maintenance: 2 tablets once daily as needed (Max: 8 tablets daily) |
| 514 | Diphtheria and Tetanus Vaccine Injection | J07AM51963P3001XX | C+ | Immunisation against diphtheria and tetanus. | 0.5ml by deep SC or IM injection. Dosing is according to Immunisation Schedule under NIP. | |
| 515 | Diphtheria Antitoxin Injection | J07AF01000P3001XX | B | Diphtheria | Therapeutic: 10,000 - 30,000 units by IM or IV. Increase to 40,000 - 100,000 units in severe cases. Doses up to 30,000 units may be given IM | |
| 516 | Diphtheria, Pertussis, Tetanus Vaccine Injection | J07AJ52963P3001XX | C+ | Immunisation against diphtheria, pertussis and tetanus. | 0.5ml by IM. Dosing is according to Immunisation Schedule under NIP. | |
| 517 | Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content) Suspension for injection (Tdap) | J07AJ52-963-P30-01-XXX | C+ | Indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy. | None | A single 0.5 ml dose of the vaccine is recommended for pregnant women during the second or the third trimester of pregnancy. For deep intramuscular injection, preferably in the deltoid region |
| 518 | Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Virus, Haemophilus Influenza Type B (DTaP-IPV-HiB) Vaccine Injection | J07CA06963P3001XX | C+ | Immunisation of children against Diphtheria, Tetanus, Acellular Pertussis, Polio and Haemophilus Influenza Type B infection. | 0.5ml by IM. Dosing is according to Immunisation Schedule under NIP. | |
| 519 | Diphtheria, Tetanus, Pertussis (Acellular, component), Hepatitis B (rDNA), Poliomyelitis (Inactivated) and Haemophilus Influenzae Type B Conjugate Vaccine (adsorbed) (DTaP- IPV-HB-Hib) Injection | J07CA09-963-P30-02-001 | C+ | For primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). | Not applicable | Dosing is according to Immunisation Schedule under NIP: Primary: Dose of 0.5ml to be given by IM at 2, 3 & 5 months of age. Booster: Dose of 0.5ml to be given by IM at 18 months of age. |
| 520 | Dithranol 0.1 - 5% in Vaseline/ Ointment | D05AC01000G5001XX | A | Short contact treatment for plaque psoriasis and alopecia areata | For application to skin or scalp. 0.1-0.5% suitable for overnight treatment. 1-2% for max 1 hour. | |
| 521 | Dithranol 1 % in Lassars Paste | D05AC01000G6001XX | A | Treatment of quiescent or chronic psoriasis of the skin, scalp and alopecia areata | Apply liberally and carefully to the lesions with a suitable applicator. A dressing may be applied | |
| 522 | Dobutamine 12.5mg/ml Injection | C01CA07-110-P30-01-XX | A | Hypotension and heart failure | None | Initial 0.5-1 mcg/kg/min by IV, maintenance 2.5-10mcg/kg/min. Frequently,doses up to 20mcg/kg/min are required for adequate hemodynamic improvement. On rare occasions,infusion rates up to 40mcg/kg/min |
| 523 | Docetaxel 20mg/ml Injection | L01CD02-000-P30-03-XXX | A* | i) Breast Cancer ii) Non-small cell lung cancer iii) Prostate cancer iv) Gastric adenocarcinoma v) Head and neck cancer vi) Ovarian cancer | Two dosing regimens: a. 50 mg/m2 every 2 weeks, intravenous b. 75 to 100 mg/m2 every 3 weeks, intravenous. Dosing is according to product insert/protocol. | |
| 524 | Docetaxel 40mg/ml Injection | L01CD0-000-P30-02-XXX | A* | i) Breast Cancer ii) Non-small cell lung cancer iii) Prostate cancer iv) Gastric adenocarcinoma v) Head and neck cancer vi)Ovarian cancer | Two dosing regimens: a. 50 mg/m2 every 2 weeks, intravenous b. 75 to 100 mg/m2 every 3 weeks, intravenous. Dosing is according to product insert/protocol. | |
| 525 | Dolutegravir 50mg Tablet | J05AX12-000-T32-01-XXX | A/KK | Dolutegravir is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. | For patients who are : - not able to tolerate; or - failing treatment or resistant to first line therapy (efavirenz and nevirapine). | i) HIV-1 patients without documented or clinically suspected resistance to the integrase class: 50 mg (one tablet), once daily, orally. ii) HIV-1 patients with resistance to the integrase class: 50 mg (one tablet), twice daily, orally. |
| 526 | Dolutegravir 50mg, Lamivudine 300mg, Tenofovir Disoproxil Fumarate 300mg Film-Coated Tablets | J05AR27-964-T32-01-XXX | A/KK | Indicated for use alone as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing 40 kg or greater. | None | One tablet once daily |
| 527 | Domperidone 1 mg/ml Suspension | A03FA03000L8001XX | B | Nausea, vomiting, dyspepsia, gastro-esophageal reflux | Adults and adolescents ≥ 12 years of age and weighing ≥ 35kg & children < 12 years of age and weighing ≥ 35kg: 10ml three to four times per day. Maximum dose: 40mg/day. Adults and adolescents (≥ 12 years of age) weighing < 35kg: 0.25mg/kg three to four times per day. Maximum dose: 35mg/day. | |
| 528 | Domperidone 10 mg Tablet | A03FA03253T1001XX | B | Nausea, vomiting, dyspepsia, gastro-esophageal reflux | Adults and adolescents ≥ 12 years of age and weighing ≥ 35kg & children < 12 years of age and weighing ≥ 35kg: 10mg three to four times per day. Maximum dose: 40mg/day | |
| 529 | Donepezil HCl 10 mg Tablet | N06DA02-110-T10-02-XXX | A/KK | Treatment of mild, moderate and severe dementia in Alzheimer's disease | Psychiatrists, Neurologists, Geriatricians, Family Medicine Specialists trained in Mental Health Disorders | 5 - 10 mg once daily at bedtime. Maximum 10 mg daily |
| 530 | Donepezil HCl 10mg Orodispersible Tablet | N06DA02-110-T40-02-XXX | A* | Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease | Psychiatrists, neurologists and geriatricians only | Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg. |
| 531 | Donepezil HCl 5 mg Tablet | N06DA02-110-T10-01-XXX | A/KK | Treatment of mild, moderate and severe dementia in Alzheimer's disease. | Psychiatrists, Neurologists, Geriatricians, Family Medicine Specialists trained in Mental Health Disorders | 5 - 10 mg once daily at bedtime. Maximum 10 mg daily |
| 532 | Donepezil HCl 5mg Orodispersible Tablet | N06DA02-110-T40-01-XXX | A* | Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease | Psychiatrists, neurologists and geriatricians only | Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg. |
| 533 | Dopamine HCl 40 mg/ml Injection | C01CA04110P3001XX | B | Non-hypovolemic hypotension | None | Initial dose 2-5 mcg/kg/min with incremental changes of 5-10 mcg/kg/min at 10-15 minutes intervals until adequate response is noted. Most patients are maintained at less than 20 mcg/kg/min. If dosage exceeds 50 mcg/kg/min, assess renal function frequently |
| 534 | Dorzolamide HCl 2% Ophthalmic Solution | S01EC03-110-D20-01-XXX | A* | All glaucoma patients where beta-blockers are contraindicated and when intraocular pressure is not well controlled by other drugs | None | Monotherapy : 1 drop 3 times daily. Adjunctive therapy with an ophthalmic beta-blocker : 1 drop 2 times daily. When substituting for another ophthalmic antiglaucoma agent with this product, discontinue the other agent after proper dosing on one day and start Trusopt on the next day. If more than 1 topical ophthalmic drug is used, the drugs should be administered at least 10 mins apart |
| 535 | Dothiepin HCl 25 mg Capsule | N06AA16110C1001XX | A | Depression of any aetiology | Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended | |
| 536 | Dothiepin HCl 75 mg Tablet | N06AA16110T1001XX | A | Depression of any aetiology | Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended | |
| 537 | Doxazosin Mesilate 4mg CR Tablet | C02CA04196T5001XX | A* | Benign Prostatic Hyperplasia | None | 4 mg once daily to maximum 8mg/day |
| 538 | Doxorubicin HCl 2mg/mL Injection | L01DB01110P4002XX | A | i) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) Leukaemia (ALL induction) iii) Multiple myeloma | i) 30 - 75 mg/m2 IV as a single dose at 21 day intervals ii) 25 - 45 mg/m2 once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m2 due to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m2 to maximum 360 mg/m2 iii) 9 mg/m2 over 24 hours infusion for 4 days at monthly intervals | |
| 539 | Doxycycline 100mg Capsule | J01AA02-000-C10-01-XXX | B | Prophylaxis and treatment for infections due to susceptible organisms. | None | Prophylaxis 100-200mg daily or weekly Treatment 100-300mg daily Dosing is individualised based on type of infections and according to product insert/protocol |
| 540 | Doxycycline 100mg Tablet | J01AA02-000-T10-01-XXX | B | Prophylaxis and treatment for infections due to susceptible organisms | None | Prophylaxis 100-200mg daily or weekly Treatment 100-300mg daily Dosing is individualised based on type of infections and according to product insert/protocol |